VALRUBICIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Valrubicin, and what generic alternatives are available?
Valrubicin is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in VALRUBICIN is valrubicin. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the valrubicin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valrubicin
A generic version of VALRUBICIN was approved as valrubicin by HIKMA on April 19th, 2019.
Summary for VALRUBICIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 58 |
Clinical Trials: | 6 |
Patent Applications: | 4,738 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VALRUBICIN |
DailyMed Link: | VALRUBICIN at DailyMed |
Recent Clinical Trials for VALRUBICIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Endo Pharmaceuticals | Phase 1 |
H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
Endo Pharmaceuticals | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for VALRUBICIN
US Patents and Regulatory Information for VALRUBICIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | VALRUBICIN | valrubicin | SOLUTION;INTRAVESICAL | 206430-001 | Apr 19, 2019 | AO | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |